Imagine being a mother with epilepsy, forced to choose between controlling your seizures and risking your unborn child’s health. This is the heartbreaking dilemma faced by thousands of women worldwide who rely on valproic acid (VPA), a highly effective anti-seizure medication. But here’s where it gets controversial: while VPA is a lifeline for many, it’s also linked to a 10% risk of structural birth defects in babies exposed to it during pregnancy. Now, a groundbreaking study led by Monash University offers a glimmer of hope, paving the way for a genetic test that could revolutionize how we approach this complex issue.
Valproic acid (VPA) stands as a cornerstone treatment for epilepsy, often the only option for effective seizure control. Yet, its use is increasingly restricted in several countries due to the alarming rate of birth defects associated with its use during pregnancy. These defects range from severe neural tube abnormalities to milder issues like cleft palate, leaving expectant mothers and their doctors in a precarious position. But what if we could identify women who could safely take VPA without risking their baby’s health? This is precisely what researchers at Monash University, in collaboration with Australian and international experts, are working towards.
Published in the prestigious journal Neurology, the study uncovers a specific DNA sequence variation in mothers that could predict whether their child is at risk of harm from VPA during pregnancy. The research reveals that VPA interferes with molecules that bind to DNA and regulate gene activity during fetal development. Genetic variants within a mother’s DNA can disrupt this binding process, explaining why only some fetuses are affected. This discovery is a game-changer, as it opens the door to personalized medicine for pregnant women with epilepsy.
And this is the part most people miss: The study’s lead researcher, Dr. Alison Anderson, emphasizes the critical balance clinicians must strike. On one hand, uncontrolled seizures in the mother pose a significant risk of injury or death. On the other, the potential harm to the fetus from VPA cannot be ignored. For some women, VPA is the only medication that effectively manages their seizures. The goal, Dr. Anderson explains, is to develop a genetic test that identifies women without the genetic risk of birth defects, allowing them to continue their life-saving treatment safely.
Senior researcher Professor Terence O’Brien highlights the pivotal role of pregnancy registries in this research. By pooling data from registries worldwide, the team gained unprecedented insights into the outcomes of pregnant women with epilepsy and their babies, both with and without medication. This wealth of information brings us closer to precision medicine, where treatment decisions are tailored to an individual’s genetic profile rather than relying on trial and error.
In a related study published in Neurology last November, the same research group employed deep learning models to analyze genomic and clinical data, predicting responses to first-line epilepsy treatments in newly diagnosed patients. The next phase of their research will leverage cutting-edge deep learning tools and Monash University’s new MAVERIC supercomputer to predict how genetic variants influence drug therapy and adverse effects.
But here’s the controversial question: As we move toward personalized medicine, how do we ensure equitable access to these advancements? Will genetic testing become a privilege for some, leaving others to face difficult choices without this critical information? We’d love to hear your thoughts in the comments below. Could this genetic test be the key to resolving the VPA dilemma, or does it raise more questions than it answers?
For more details, read the full research paper here.
Media Enquiries:
Toni Brient, Media and Communications Manager
Phone: +61 423 964 191
Email: [emailprotected]
General Media Enquiries:
Monash Media
Phone: +61 3 9903 4840
Email: [emailprotected]
Explore more Monash media stories here.
